Appetite Suppression Peptides

Q: Will I regain the weight when I stop?

Probably, yes — up to two-thirds within 12 months of discontinuation in the current data. The mechanism is physiology (rising ghrelin, falling metabolic rate, appetite rebound), not willpower. Plan these drugs as long-term chronic-disease therapy, not as a short course. If discontinuation is necessary, tapering protocols and extended-interval dosing may reduce the severity of regain — but the evidence base is emerging rather than settled.

Q: Is the newest drug always the best choice?

Efficacy-wise, the multi-agonist trend is real — more pathways correlate with more weight loss in current trials. But more pathways also means more surface area for long-term unknowns. Semaglutide has ~15 years of real-world data. Tirzepatide has ~3. Retatrutide is investigational. For patients whose weight loss target is met by semaglutide, the mature safety dossier is a real argument against escalation. For patients who need 20%+, the multi-agonist choice is defensible despite the thinner long-term data.

Q: Can I get these compounded more cheaply?

Technically yes; safely no. US case series document 10-fold overdoses from compounded semaglutide manually measured from multi-dose vials — the math error is trivial, and the consequences have been severe. Counterfeit peptides have been found to contain clandestine insulin (life-threatening hypoglycaemia) and amphetamines. Pharmaceutical prefilled pens are the safety-significant difference, not the marketing story. If cost is the barrier, that is a real conversation — but compounded vials from aesthetic spas are not the safe alternative.

Q: What happened with AOD-9604 and osteoarthritis?

AOD-9604 was developed as a weight-loss drug in the 1990s and failed its Phase IIb trial for that indication in 2007 — weight-loss effect was not statistically significant over placebo despite an excellent safety profile across 900+ patients. The development programme was terminated for obesity. Recent research has revisited it for osteoarthritis and cartilage regeneration, where early data is promising. It is a reminder that 'failed in trial X' is not the same as 'doesn't do anything'. For appetite suppression specifically: AOD-9604 did not demonstrate clinical benefit. Do not buy it for weight loss.

Appetite Suppression

GLP-1 agonists became a cultural phenomenon because they deliver dramatic short-term weight loss. The honest framing is chronic-disease pharmacology — effective while taken, compensation when withdrawn, best used alongside the nutritional foundation the drug amplifies.

Pinned

April 19, 20261 views

1.Four Peptide Classes, One Target

Peptide-based appetite suppression splits into four clinically distinct classes, each acting on a different point of the gut-brain satiety axis:

Incretin receptor agonists — GLP-1 (semaglutide, liraglutide), dual GLP-1/GIP (tirzepatide), triple GLP-1/GIP/glucagon (retatrutide). The dominant class with Tier-1 evidence and increasingly dramatic weight-loss numbers as pathway count rises.
Amylin analogs — cagrilintide. Acts on the area postrema hindbrain satiety centre, a different neural substrate from GLP-1, which is why combination with GLP-1s (CagriSema) produces additive effects.
Hypothalamic peptides — BRP (brain-region-specific peptide, 12 amino acids). Early-stage, animal-only at the time of writing, but mechanistically interesting because it suppresses appetite by ~50% in rodents without GI side effects.
Growth-hormone fragments — AOD-9604. Officially failed its weight-loss trial in 2007 and terminated. Currently being revisited for osteoarthritis and cartilage regeneration. A cautionary tale about what 'failed' means.

The arms race is real. Semaglutide lands ~15% weight loss. Tirzepatide ~22%. Retatrutide ~24% in Phase 2. Each added pathway buys more weight loss — and more surface area for unknown long-term effects. The class is progressing faster than the long-term safety data.

“The drugs are not broken. The long-term safety data is just running behind them — and the weight regain on discontinuation is the feature that keeps getting re-discovered.”

2.The Multi-Pathway Arms Race

The clearest pattern in the last five years of this class is that adding metabolic pathways adds weight loss — linearly, in current trial data, at the cost of more side effects and more long-term unknowns.

Semaglutide — one pathway, ~15%

GLP-1 agonism alone. Stimulates pancreatic β-cell insulin secretion, delays gastric emptying, inhibits orexigenic NPY/AgRP neurons, activates anorexigenic POMC neurons. The mechanism is now textbook. Phase-3 trials in obesity deliver ~15% mean weight loss at 2.4 mg weekly maintenance.

Tirzepatide — two pathways, ~22%

Adds GIPR agonism. The GIP pathway enhances fat metabolism and insulin sensitisation in adipose tissue and may reduce nausea relative to single-pathway agents. Phase-3 delivers ~22% mean weight loss. The 'GIP paradox' — where GIP knockout mice are protected from obesity yet GIP agonism drives weight loss — remains unresolved but clinically the dual agonist wins.

Retatrutide — three pathways, ~24%

Adds glucagon receptor (GCGR) agonism. GCGR activates brown adipose tissue (BAT) thermogenesis — or, in an unresolved but defensible alternative view, drives energy expenditure via liver-produced FGF21 rather than direct BAT effect. Phase 2 delivers ~24.2% weight loss at 12 mg. Phase 3 is ongoing. The cardiovascular-outcome story is still to be written.

The next tier — CagriSema and beyond

Cagrilintide (amylin analog) combined with semaglutide — CagriSema — engages a non-GLP-1 satiety pathway in addition to GLP-1. Early trial data suggests additive weight loss. Theoretical quadruple-pathway combinations (retatrutide + cagrilintide) exist only on paper.

4.The Frontier — Amylin, Hypothalamic Peptides, and Resurrected Fragments

Beyond the incretin core, the appetite-suppression landscape branches into three smaller classes that are genuinely distinct mechanisms — not 'me-too' molecules.

Cagrilintide — amylin analog

Amylin is a pancreatic hormone co-secreted with insulin that acts on the area postrema in the hindbrain — a different satiety substrate from GLP-1's hypothalamic target. Cagrilintide, a long-acting amylin analog, produces modest monotherapy weight loss (~10%) and substantial additive effect when combined with semaglutide (CagriSema, ~15–20% additional to GLP-1 alone in early trials).

BRP — hypothalamic 12-mer

Brain-region-specific peptide, a 12-amino-acid molecule acting directly in the hypothalamus. Suppresses appetite by ~50% in animal models with a notably clean side-effect profile — no GI symptoms reported. Currently pre-clinical. If it translates to humans at anywhere near that efficacy without GI cost, it would be a significant advance. The conditional is doing a lot of work in that sentence.

AOD-9604 — the resurrected fragment

Anti-Obesity Drug 9604 was a 16-amino-acid fragment of hGH's C-terminal lipolytic region. Designed to reproduce hGH's fat-burning without the metabolic liabilities. Six human trials with 900+ participants demonstrated 'excellent safety' — and failed to hit statistical significance for weight loss in the Phase IIb trial. Development terminated in 2007.

The second life: recent research suggests AOD-9604 may have applications in osteoarthritis and cartilage regeneration. A compound that could not clear its primary endpoint may yet land in a completely different therapeutic area. It is also worth noting that AOD-9604 has a 4-minute plasma half-life — if you are reading recreational dosing advice online, that half-life is the reason the advice is usually 'dose aggressively' and that recommendation is not supported by the clinical evidence.

Cagrilintide (amylin analog)

Half-life · Approximately 180 hours (~7.5 days).Route · Subcutaneous weekly injection.Cycle · Chronic use intended; no established cycling protocol.Safe default · Per clinical trial protocol — not yet approved for outpatient prescribing at time of writing.

“AOD-9604 failed its weight-loss trial. It may yet rehabilitate joints. The lesson is that 'failed in trial X' is not the same as 'failed'.”

5.Safety, Side Effects, and the GI Ceiling

GI side effects are the dominant near-term clinical reality. Nausea, vomiting, diarrhoea, and constipation affect 70–85% of patients on GLP-1 agonists — most commonly during titration. For most users the symptoms are manageable with slow titration; for a substantial minority they drive discontinuation.

The confirmed risk surface

Black-box warning for medullary thyroid cancer (rodent-data, unconfirmed in humans, absolute contraindication with MEN2). Confirmed gallbladder disorders — rapid weight loss on high-dose GLP-1 therapy increases cholelithiasis and cholecystitis rates. Acute kidney injury secondary to volume contraction. Dose-dependent sinus tachycardia on dual and triple agonists. Perioperative aspiration risk — GLP-1 agonists must be disclosed to anaesthetic teams and discontinued per current anaesthesia guidance.

The 'food noise' side effect

Patients on GLP-1 therapy often describe a reduction in intrusive food thoughts ('food noise'). This is the mechanism working — hypothalamic orexigenic suppression. It can shade into anhedonia (loss of pleasure in food and other rewarding activities) in some patients, and it is a genuinely under-discussed dimension of what these drugs do. Under-characterised but reversible on discontinuation.

Drug-supplement interactions

Two under-appreciated interactions. Berberine and chromium — each has glucose-lowering effects that can stack with GLP-1 therapy, driving hypoglycaemia. Oral contraceptives — GLP-1 agonists and tirzepatide delay gastric emptying enough to reduce oral contraceptive efficacy, especially during titration. Backup contraception is the right posture for the first months of therapy.

The sourcing catastrophe

The single highest-impact safety decision in this class is not pharmacological — it is supply chain. US case series document 10-fold overdoses from compounded semaglutide manually measured from multi-dose vials. Counterfeit peptides have been found to contain clandestine insulin (life-threatening hypoglycaemia) and amphetamines (cardiovascular crisis). 'Research grade' and aesthetic-spa compounded product are the two dominant sources of preventable harm in this class.

⚠️ CRITICAL: Three non-negotiable safety items. First: source pharmaceutical-grade product with lot-matched certificate of analysis — compounded and 'research grade' peptides have produced 10-fold overdoses and drug-contamination deaths in US reporting. Second: discontinue GLP-1 agonists before elective anaesthesia per current guidance (typically 1 week for weekly agents) — regurgitation and aspiration risk is the documented concern. Third: check interactions with oral contraceptives (reduced efficacy during titration), berberine/chromium (additive hypoglycaemia), and insulin/sulfonylureas (mandatory dose reduction before adding GLP-1).

Frequently Asked Questions

How much weight should I expect to lose?

Class-dependent. Semaglutide (single-pathway GLP-1): ~15% of body weight at target dose over ~12 months. Tirzepatide (dual GLP-1/GIP): ~22%. Retatrutide (investigational triple agonist): ~24% in Phase 2. Individual variation is significant — age, baseline BMI, lifestyle support, and dose tolerance all matter. Responders vs poor-responders split is real, and if weight loss at 3 months is <5% of baseline, that is a signal to discuss dose, adherence, or class switch with the prescriber.

Will I regain the weight when I stop?

Probably, yes — up to two-thirds within 12 months of discontinuation in the current data. The mechanism is physiology (rising ghrelin, falling metabolic rate, appetite rebound), not willpower. Plan these drugs as long-term chronic-disease therapy, not as a short course. If discontinuation is necessary, tapering protocols and extended-interval dosing may reduce the severity of regain — but the evidence base is emerging rather than settled.

Is the newest drug always the best choice?

Efficacy-wise, the multi-agonist trend is real — more pathways correlate with more weight loss in current trials. But more pathways also means more surface area for long-term unknowns. Semaglutide has ~15 years of real-world data. Tirzepatide has ~3. Retatrutide is investigational. For patients whose weight loss target is met by semaglutide, the mature safety dossier is a real argument against escalation. For patients who need 20%+, the multi-agonist choice is defensible despite the thinner long-term data.

Can I get these compounded more cheaply?

Technically yes; safely no. US case series document 10-fold overdoses from compounded semaglutide manually measured from multi-dose vials — the math error is trivial, and the consequences have been severe. Counterfeit peptides have been found to contain clandestine insulin (life-threatening hypoglycaemia) and amphetamines. Pharmaceutical prefilled pens are the safety-significant difference, not the marketing story. If cost is the barrier, that is a real conversation — but compounded vials from aesthetic spas are not the safe alternative.

What happened with AOD-9604 and osteoarthritis?

AOD-9604 was developed as a weight-loss drug in the 1990s and failed its Phase IIb trial for that indication in 2007 — weight-loss effect was not statistically significant over placebo despite an excellent safety profile across 900+ patients. The development programme was terminated for obesity. Recent research has revisited it for osteoarthritis and cartilage regeneration, where early data is promising. It is a reminder that 'failed in trial X' is not the same as 'doesn't do anything'. For appetite suppression specifically: AOD-9604 did not demonstrate clinical benefit. Do not buy it for weight loss.

Appetite Suppression

1.Four Peptide Classes, One Target

2.The Multi-Pathway Arms Race

Semaglutide — one pathway, ~15%

Tirzepatide — two pathways, ~22%

Retatrutide — three pathways, ~24%

The next tier — CagriSema and beyond

Explore This Protocol

Safety Triggers

Research Gaps

Contrarian Views

Protocol Reference

Stay Ahead of the Research

3.The Weight-Regain Problem